Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 254 entries
View as:

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

Phase: N/A Priority: Normal
NCT ID: NCT01227824 Org: User:
Start: 10/19/10 End: 12/27/16 Due: 12/27/17

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Phase: N/A Priority: Normal
NCT ID: NCT01263015 Org: User:
Start: 02/01/11 End: 12/03/15 Due: 12/03/16

A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men

Phase: N/A Priority: Normal
NCT ID: NCT03422172 Org: User:
Start: 04/10/18 End: 04/20/20 Due: 04/20/21

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

Phase: N/A Priority: Normal
NCT ID: NCT02027454 Org: User:
Start: 01/31/14 End: 06/30/14 Due: 06/30/15

First Time in Human Study of Long Acting VH4524184 Formulations

Phase: N/A Priority: Normal
NCT ID: NCT06310551 Org: User:
Start: 03/21/24 End: 01/21/28 Due: 01/21/29

Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine

Phase: N/A Priority: Normal
NCT ID: NCT00098293 Org: User:
Start: 11/30/04 End: 12/31/12 Due: 12/31/13

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

Phase: N/A Priority: Normal
NCT ID: NCT02831764 Org: User:
Start: 07/18/16 End: 06/29/22 Due: 06/29/23

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

Phase: N/A Priority: Normal
NCT ID: NCT01384734 Org: User:
Start: 07/26/11 End: 05/12/17 Due: 05/12/18

PENTA Fosamprenavir Study

Phase: N/A Priority: Normal
NCT ID: NCT01077635 Org: User:
Start: 10/31/08 End: 09/30/11 Due: 09/30/12

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

Phase: N/A Priority: Normal
NCT ID: NCT06533280 Org: User:
Start: 08/02/24 End: 08/14/24 Due: 08/14/25

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

Phase: N/A Priority: Normal
NCT ID: NCT02951052 Org: User:
Start: 10/28/16 End: 12/31/25 Due: 12/31/26

VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

Phase: N/A Priority: Normal
NCT ID: NCT06214052 Org: User:
Start: 02/07/24 End: 06/12/24 Due: 06/12/25

GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04493684 Org: User:
Start: 07/31/20 End: 08/30/21 Due: 08/30/22

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00098722 Org: User:
Start: 12/31/04 End: 04/30/11 Due: 04/30/12

Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01597895 Org: User:
Start: 07/31/12 End: 08/31/12 Due: 08/31/13

Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection

Phase: N/A Priority: Normal
NCT ID: NCT00440947 Org: User:
Start: 03/31/07 End: 07/31/10 Due: 07/31/11

Dolutegravir Pediatric Liquid Formulation Study

Phase: N/A Priority: Normal
NCT ID: NCT03921723 Org: User:
Start: 05/07/19 End: 07/25/19 Due: 07/25/20

ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection

Phase: N/A Priority: Normal
NCT ID: NCT02075593 Org: User:
Start: 12/17/14 End: 09/15/21 Due: 09/15/22

Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)

Phase: N/A Priority: Normal
NCT ID: NCT00920426 Org: User:
Start: 06/09/09 End: 08/13/09 Due: 08/13/10

Multicenter, Safety Study Of Maraviroc

Phase: N/A Priority: Normal
NCT ID: NCT00478231 Org: User:
Start: 07/31/07 End: 09/30/10 Due: 09/30/11

Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.

Phase: N/A Priority: Normal
NCT ID: NCT02206711 Org: User:
Start: 08/08/14 End: 09/09/14 Due: 09/09/15

A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults

Phase: N/A Priority: Normal
NCT ID: NCT03784079 Org: User:
Start: 01/31/19 End: 02/06/20 Due: 02/06/21

Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00071760 Org: User:
Start: 10/23/03 End: 03/29/22 Due: 03/29/23

Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc

Phase: N/A Priority: Normal
NCT ID: NCT00853840 Org: User:
Start: 04/30/08 End: 05/31/08 Due: 05/31/09

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01140412 Org: User:
Start: 07/31/10 End: 10/31/10 Due: 10/31/11